252 related articles for article (PubMed ID: 35679743)
1. Advances in the treatment of extramedullary disease in multiple myeloma.
Li Y; Sun Z; Qu X
Transl Oncol; 2022 Aug; 22():101465. PubMed ID: 35679743
[TBL] [Abstract][Full Text] [Related]
2. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
Wang Y; Liu A; Xu T; Yin J; Chen W
Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide-based therapy for extramedullary multiple myeloma.
Li Y; Ji J; Lu H; Li J; Qu X
Hematology; 2022 Dec; 27(1):88-94. PubMed ID: 35068387
[TBL] [Abstract][Full Text] [Related]
4. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
[No Abstract] [Full Text] [Related]
5. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
[TBL] [Abstract][Full Text] [Related]
6. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease.
Abdallah AO; Mohyuddin GR; Ahmed N; Mohan M; Cui W; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S; Atrash S
EJHaem; 2021 Nov; 2(4):757-764. PubMed ID: 35845187
[TBL] [Abstract][Full Text] [Related]
9. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
11. [Treatment algorithms for multiple myeloma in Japan].
Ozaki S
Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
[TBL] [Abstract][Full Text] [Related]
12. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.
Du J; Zhuang J
Chronic Dis Transl Med; 2021 Dec; 7(4):220-226. PubMed ID: 34786541
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
14. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
